Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project Authors: Alessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, Samantha Bove, Maria Colomba Comes, Ondřej Fiala, Akihiro Yano, Kirstin Binz, Ray Manneh Kopp, Jawaher Ansari, Renate Pichler, Oronzo Brunetti, Daniele Santini, Alina Pirstuk, Annarita Fanizzi, Gerardo Cazzato, Mario Della Mura, Mobin Safi, Alvaro Pinto, Alessia Mennitto, Raffaella Massafra, Veronica Mollica, Yüksel Ürün, Matteo Rosellini, Matteo Santoni, Francesco Massari Published: 2026 ABSTRACT BackgroundEnfortumab vedotin (EV) is approved for the treatment of metastatic urothelial carcinoma (mUC), as monotherapy or in combination with immune checkpoint inhibitors (ICIs), following the results of recent practice-changing clinical trials, such as EV-301 and EV-302. However, EV-301 included only patients with Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0 or 1, while ECOG-PS 2 mUC patients were excluded.ObjectiveIn clinical settings, the benefit of EV for this group of vulnerable patients remains a significant and yet unresolved question. The aim of our study was to evaluate the impact of ECOG-PS on survival outcomes in patients treated with EV using the ARON global real-world database.Patients and methodsA total of 483 mUC patients with ECOG-PS 0–1 and 85 with ECOG-PS 2 and treated with EV were included. The coprimary endpoints were Overall Survival (OS) and Progression-Free Survival (PFS) to compare the clinical outcomes of mUC patients with ECOG-PS 2 versus ECOG-PS 0 or 1. The secondary endpoints included the comparison of OS and PFS in these two patient groups according to metastatic sites (liver, bone, lung, lymph nodes, brain, soft tissue).ResultsThe median OS was 13.63 months (95% CI 11.9-15.57) and 6.34 months (95% CI 4.96–8.48) in mUC patients with ECOG-PS 0–1 and ECOG-PS 2, respectively. Patients with ECOG-PS 2 receiving EV reported statistically significantly shorter OS compared to those with ECOG-PS 0–1 (HR 2.24; 95% CI 1.64–3.06; p < 0.001). The median PFS was 7.39 months (95% CI 6.60–8.04) and 3.98 months (95% CI 3.21–5.95) in mUC patients with ECOG-PS 0–1 and ECOG-PS 2, respectively. Patients with ECOG-PS 2 receiving EV reported statistically significantly shorter PFS compared to those with ECOG-PS 0–1 (HR 1.71; 95% CI 1.29–2.27; p < 0.001). Similarly, shorter OS and PFS was observed in ECOG-PS 2 patients with liver, bone, lung, and lymph nodes metastases, while shorter PFS was associated with lymph nodes and bone metastases.ConclusionsOur analysis showed worse survival outcomes in pretreated mUC with ECOG-PS 2 receiving EV monotherapy; however, given the retrospective design and baseline imbalances between ECOG groups, these findings should not be interpreted as evidence of reduced intrinsic EV efficacy. The outcomes of EV monotherapy in ECOG-PS 2 patients remains uncertain and can only be inferred from non-randomized prospective trials and studies based on real-world evidence. Further studies and multicentric translational collaborations are fundamental to validate these findings.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16109-9. Introduction In recent years, the treatment landscape for metastatic urothelial carcinoma (mUC) has significantly evolved, following the development of novel anticancer treatments, such as immunotherapeutics, antibody-drug conjugates (ADCs), and targeted therapies – as monotherapy or as part of combinatorial strategies [1]. Enfortumab vedotin (EV) is an ADC composed of a monoclonal antibody targeting Nectin-4, a cell adhesion molecule highly expressed in urothelial carcinoma, linked to monomethyl auristatin E (MMAE) [2, 3]. The practice-changing phase 3 EV-301 compared EV with standard-of-care chemotherapy (docetaxel, paclitaxel, or vinflunine) in patients with mUC who had progressed after platinum-based chemotherapy and immunotherapy. EV demonstrated a significant survival benefit, with a median Overall Survival (OS) of 12.9 months compared to 8.9 months in the chemotherapy group (HR 0.70 (95% CI 0.58–0.85), p = 0.00015) [4, 5]. However, this analysis did not include patients with poor performance status – such as Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 2, leaving a critical gap in knowledge regarding the efficacy of EV in this subgroup [6]. Of note, a significant percentage of patients in poor clinical conditions receive EV in real-world clinical practice, even though there is limited evidence regarding the effectiveness of this new treatment approach for mUC patients with ECOG PS 2 [7]. At the same time, while the ECOG-PS is commonly used, a considerable heterogeneity has traditionally been observed, something that highlights the subjectivity and variability in measuring PS as evaluated by the ECOG scale [8]. The aim of our study was to evaluate the impact of ECOG-PS on survival outcomes in patients treated with EV according to the ARON global real-world retrospective database. This analysis aims to fill a critical gap in knowledge by evaluating the impact of ECOG-PS on outcomes with EV in patients with mUC and ECOG-PS 2. Patients and methods Study Population We retrospectively analyzed clinical data from mUC patients enrolled in ARON-2EV (Clinical Trial Number: NCT05290038), an international multicenter observational study aimed at evaluating data on EV in patients with mUC who had previously progressed on platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor. Because prior ICI exposure included maintenance avelumab after first-line platinum-based chemotherapy or a later-line PD-1/PD-L1 inhibitors, the exact numerical treatment line of EV could not be assigned uniformly across the cohort. The ARON-2EV involved 56 oncological centers from 15 countries. The clinical data were collected between 1 January 2022 and 30 April 2024 and were extracted at each participating center. Patients with missing outcome data were excluded from the analysis. EV was administered intravenously as a single agent in the standard approved schedule, and EV therapy was continued until disease progression, unacceptable toxicity, or patient refusal. Physical examination and laboratory tests and computed tomography (CT) scans were performed following standard local procedures. The study protocol was approved on 28 September 2023 by the Ethical Committee of the coordinating center (Marche Region, Italy – no. 2022 39/7875) and by the Institutional Review Boards of participating centers. The study was conducted according to Good Clinical Practice (GCP) and International Ethical Guidelines for Biomedical Research, and the protocol has been designed with the ethical principles laid out in the Declaration of Helsinki on human experimentation. Study endpoints The coprimary endpoints were OS and Progression-Free Survival (PFS) in order to compare the clinical outcomes of mUC patients with ECOG-PS 2 versus ECOG-PS 0 or 1. The secondary endpoints included the comparison of OS and PFS in these two patient groups according to metastatic sites (liver, bone, lung, lymph nodes, brain, soft tissue). OS was calculated from the start of EV treatment to death from any cause. Patients alive or lost at follow-up at the time of the analysis were censored at the last follow-up visit. PFS was calculated from the first administration of EV to documented disease progression or death from any cause, whichever occurred first. Patients without disease progression or death or lost at follow-up at the time of the analysis were censored at the last follow-up visit. Radiologic assessments were performed according to local practice. Progression was assessed by local investigators using RECIST criteria and recorded in the study database. In absence of blinded independent central review and harmonized assessment intervals across centers, PFS should be interpreted as investigator-assessed PFS based on local RECIST assessments. Statistical analysis The Kaplan–Meier method with Rothman’s 95% confidence intervals (CI) was used to estimate survival curves of OS and PFS. Comparisons between survival curves were performed using the log-rank test. An initial univariable Cox model including ECOG-PS only was fitted, and hazard ratios (HRs) with 95% confidence intervals (CIs) were provided. A prespecified multivariable Cox proportional hazard model was subsequently constructed in the overall cohort to quantify the independent association between ECOG-PS (2 vs. 0–1) and OS or PFS. Adjustment was performed a priori for sex, age, bone metastases, liver metastases, tumour histology. The proportional hazards assumption was examined using Schoenfeld residuals. When evidence of PH violation was observed, a sensitivity analysis was performed by refitting the Cox model, with a time-varying coefficient for ECOG-PS. As a sensitivity analysis, the same multivariable Cox proportional hazards model was repeated after additional adjustment for prior immune checkpoint inhibitors (ICIs: avelumab, pembrolizumab, atezolizumab/nivolumab). To explore prognostic factors in ECOG-PS 2 patients, univariable and multivariable Cox models for OS and PFS were fitted. The prespecified variables included age, tumor histology, primary tumor site, liver and bone metastases. Given the non-randomized observational design and the expected prognostic differences between ECOG-PS group, adjusted analyses were intended to estimate the independent association between ECOG-PS and outcomes, rather than to infer differential causal efficacy of EV across performance-status categories. Baseline characteristics were summarized using all available data for each variable. Missing data were handled using a complete-case approach for univariable and multivariable regression analyses; no imputation was performed. Safety data were abstracted from medical charts and institutional records. Safety analyses focused on pre-specified EV-related toxicities of interest (cutaneous toxicity, peripheral neuropathy, diarrhea, and diabetes/hyperglycemia). Adverse events (AEs) were collected retrospectively and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. We summarized (i) the proportion of patients experiencing at least one grade 3–4 (G3-4) event among these prespecified toxicities (≥ 1 G3-4 prespecified toxicity) and (ii) toxicity-specific G3-4 rates. Patients could experience more than one prespecified toxicity. Treatment modifications during EV were collected. Any dose reduction after treatment initiation and ≥ 1 skipped administration due to toxicity were recorded. The starting dose for the first administration was classified as standard or reduced. Prespecified key safety endpoints were: (i) ≥ 1 G3-4 prespecified toxicity, (ii) any subsequent dose reduction after EV initiation, and (iii) ≥ 1 skipped EV administration due to toxicity. Comparisons between ECOG-PS groups, and prespecified key safety endpoints, were performed using the χ² test or Fisher exact test for categorical variables, as appropriate. The level of significance was set to 0.05. R studio software (version 4.5.1 RStudio, PBC: Boston, MA, USA) was used for the statistical analyses. Results Patient population A total of 575 patients were registered across participating centers; 568 patients were included in the present analysis after exclusion of 7 patients with missing outcome data. Supplementary Table S1 shows the distribution of registred patients by participating center. A total of 483 mUC patients with ECOG-PS 0–1 and 85 with ECOG-PS 2 and treated with EV were included from the ARON-2EV dataset. The median follow-up was 10.3 months (95% CI 9.66–11.3). The clinical characteristics of the patients are summarized in Table 1. Compared with patients with ECOG 0–1, those with ECOG-PS 2 more frequently presented with adverse baseline features, including liver, bone, and brain metastases, suggesting a poorer baseline prognostic profile. Table 1Comparison of baseline characteristics between patients with ECOG-PS 0–1 and ECOG-PS 2Baseline characteristicsECOG-PS 0–1ECOG-PS 2p-value N N = 483N = 85Tumor histology, n (%)558Pure urothelial carcinoma376 (79%)61 (74%)0.350 Variants100 (21%)21 (26%) Missing73Primary tumor location, n (%)568Lower urinary tract346 (72%)65 (76%)0.358Upper urinary tract137 (28%)20 (24%)Age, years567 ≥ 70252 (52%)48 (57%)0.475 < 70230 (48%)37 (43%) Missing1Sex, n (%)565 Male362 (75%)68 (81%)0.259 Female119 (25%)16 (19%) Missing21BMI562 > 25193 (40%)23 (27%)0.019 ≤ 25284 (59%)62 (73%)6Current or former smokers, n (%)560 Yes301 (63%)59 (70%)0.217 No175 (37%)25 (30%) Missing71Prior ICI, n(%)535 Pembrolizumab216 (47%)44 (56%)0.018* Avelumab202 (44%)23 (29%) Atezolizumab /Nivolumab38 (8.3%)12 (15%) Not available276Common sites of metastasisNon-regional lymph nodes, n (%)568 Yes350 (72%)63 (74%)0.752 No133 (28%)22 (26%)Lung, n (%)568 Yes227 (47%)46 (54%)0.225 No256 (53%)39 (46%)Brain, n (%)568 Yes13 (2.7%)7 (8.2%)0.019 No470 (97%)78 (92%)Liver, n (%)568 Yes136 (28%)40 (47%)< 0.001 No347 (72%)45 (53%)Bone, n (%)568 Yes152 (31.5%)42 (49%)0.001 No331 (68.5%)43 (51%)Soft tissue, n (%)555 Yes105220.403 No37763 Missing1n (%);Statistical tests were performed excluding missing data; *Pearson’s χ² test (including 2 × 3 tables) Table 1Comparison of baseline characteristics between patients with ECOG-PS 0–1 and ECOG-PS 2Baseline characteristicsECOG-PS 0–1ECOG-PS 2p-value N N = 483N = 85Tumor histology, n (%)558Pure urothelial carcinoma376 (79%)61 (74%)0.350 Variants100 (21%)21 (26%) Missing73Primary tumor location, n (%)568Lower urinary tract346 (72%)65 (76%)0.358Upper urinary tract137 (28%)20 (24%)Age, years567 ≥ 70252 (52%)48 (57%)0.475 < 70230 (48%)37 (43%) Missing1Sex, n (%)565 Male362 (75%)68 (81%)0.259 Female119 (25%)16 (19%) Missing21BMI562 > 25193 (40%)23 (27%)0.019 ≤ 25284 (59%)62 (73%)6Current or former smokers, n (%)560 Yes301 (63%)59 (70%)0.217 No175 (37%)25 (30%) Missing71Prior ICI, n(%)535 Pembrolizumab216 (47%)44 (56%)0.018* Avelumab202 (44%)23 (29%) Atezolizumab /Nivolumab38 (8.3%)12 (15%) Not available276Common sites of metastasisNon-regional lymph nodes, n (%)568 Yes350 (72%)63 (74%)0.752 No133 (28%)22 (26%)Lung, n (%)568 Yes227 (47%)46 (54%)0.225 No256 (53%)39 (46%)Brain, n (%)568 Yes13 (2.7%)7 (8.2%)0.019 No470 (97%)78 (92%)Liver, n (%)568 Yes136 (28%)40 (47%)< 0.001 No347 (72%)45 (53%)Bone, n (%)568 Yes152 (31.5%)42 (49%)0.001 No331 (68.5%)43 (51%)Soft tissue, n (%)555 Yes105220.403 No37763 Missing1n (%);Statistical tests were performed excluding missing data; *Pearson’s χ² test (including 2 × 3 tables) Comparison of baseline characteristics between patients with ECOG-PS 0–1 and ECOG-PS 2 n (%);Statistical tests were performed excluding missing data; *Pearson’s χ² test (including 2 × 3 tables) Survival outcomes OS and PFS according to ECOG-PS 2 and 0–1 The median OS was 13.63 months (95% CI 11.9-15.57) and 6.34 months (95% CI 4.96–8.48) in mUC patients with ECOG-PS 0–1 and ECOG-PS 2, respectively. Patients with ECOG-PS 2 receiving EV reported statistically significantly shorter OS compared to those with ECOG-PS 0–1 (HR 2.24; 95% CI 1.64–3.06; p < 0.001) (Fig. 1). In patients with ECOG-PS 2, the 6-months OS rate was 54.3%, the 1-year OS rate 28.9%, and the 2-years OS rate 12.8%; in mUC patients with ECOG-PS 0–1, the 6-months OS rate was 80.7%, the 1-year OS rate 55.4%, and the 2-years OS rate 29.2%. In the primary complete-case multivariable Cox model for OS, 557 patients were included, with 241 OS events. ECOG-PS 2 was independently associated with worse OS (aHR 1.94, 95% CI 1.40–2.69; p < 0.001). Mixed tumour histology (aHR 1.38, 95% CI 1.01–1.88; p = 0.04) and the presence of liver metastases (aHR 1.48, 95% CI 1.13–1.94; p = 0.004) were also associated with shorter OS. (Table 2) The proportional hazard assumption was not violated (global Schoenfeld test p = 0.06). In the sensitivity complete-case multivariable Cox model adjusted for ICI agent, 524 patients were included, with 226 OS events. The results were materially unchanged. ECOG 2 remained associated with worse OS (aHR 1.88, 95% CI 1.33–2.65; p < 0.001), as did mixed tumor histology (aHR 1.42, 95% CI 1.03–1.95; p = 0.032) and liver metastases (aHR 1.47, 95% CI 1.12–1.95; p = 0.006) (Supplementary Table S2). Fig. 1Overall survival of the included patients Overall survival of the included patients Table 2Multivariable Cox regression analysis for OSCovariatesCox regressionaHR (95% CI)p-valueECOG-PS (2 vs. 0–1)1.94 (1.40–2.69)< 0.001Age (≥ 70 vs. <70 years)0.84 (0.65–1.08)0.175Sex (female vs. male)0.96 (0.71–1.30)0.804Histology (mixed vs. pure UC)1.38 (1.01–1.88)0.040Liver metastases (yes vs. no)1.48 (1.13–1.94)0.004Bone metastases (yes vs. no)1.07 (0.81–1.40)0.635aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, OS Overall survival Table 2Multivariable Cox regression analysis for OSCovariatesCox regressionaHR (95% CI)p-valueECOG-PS (2 vs. 0–1)1.94 (1.40–2.69)< 0.001Age (≥ 70 vs. <70 years)0.84 (0.65–1.08)0.175Sex (female vs. male)0.96 (0.71–1.30)0.804Histology (mixed vs. pure UC)1.38 (1.01–1.88)0.040Liver metastases (yes vs. no)1.48 (1.13–1.94)0.004Bone metastases (yes vs. no)1.07 (0.81–1.40)0.635aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, OS Overall survival Multivariable Cox regression analysis for OS aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, OS Overall survival The median PFS was 7.39 months (95% CI 6.60–8.04) and 3.98 months (95% CI 3.21–5.95) in mUC patients with ECOG-PS 0–1 and ECOG-PS 2, respectively. Patients with ECOG-PS 2 receiving EV reported statistically significantly shorter PFS compared to those with ECOG-PS 0–1 (HR 1.71; 95% CI 1.29–2.27; p < 0.001) (Fig. 2). In patients with ECOG-PS 2, the 6-months PFS rate was 37.4%, the 1-year PFS rate 22.9%, and the 2-years PFS rate 11.6%; in mUC patients with ECOG-PS 0–1, the 6-months PFS rate was 59.4%, the 1-year PFS rate 29.2%, and the 2-years PFS rate 18.3%. In the primary complete-case multivariable Cox model for PFS, 544 patients were included, with 325 PFS events. ECOG-PS 2 was associated with shorter PFS (aHR 1.51, 95% CI 1.12–2.03; p = 0.007). Mixed tumour histology was also associated with shorter PFS (aHR 1.61, 95% CI 1.24–2.09; p < 0.001), while the presence of liver metastases showed a weaker association with shorter PFS (aHR 1.27, 95% CI 1.00-1.61; p = 0.048). (Table 3). Given evidence of non-proportional hazards, a sensitivity analysis was performed using a Cox model with a time-varying coefficient for ECOG-PS. In this model, the association between ECOG-PS 2 and shorter PFS attenuated over time, with estimated HR of 2.77 at 1 month, 1.56 at 3 months, and 1.08 at 6 months. The time-varying ECOG term was significant (p < 0.001). Mixed tumor histology and liver metastases remained associated with shorter PFS. In the sensitivity complete-case multivariable Cox model adjusted for ICI agent, 513 patients were included, with 305 PFS events. The results were materially unchanged. ECOG 2 remained associated with worse PFS (aHR 1.48, 95% CI 1.08–2.01; p = 0.014), as did mixed tumor histology (aHR 1.66, 95% CI 1.27–2.17; p < 0.001) and liver metastases (aHR 1.29, 95% CI 1.01–1.64; p = 0.044) (Supplementary Table S3). Fig. 2Progression-free survival of the included patients Progression-free survival of the included patients Table 3Multivariable Cox regression analysis for PFSCovariatesCox regressionaHR (95% CI)p-valueECOG-PS (2 vs. 0–1)1.51 (1.12–2.03)0.007Age (≥ 70 vs. <70 years)0.93 (0.75–1.16)0.533Sex (female vs. male)1.20 (0.93–1.53)0.158Histology (mixed vs. pure UC)1.61 (1.24–2.09)< 0.001Liver metastases (yes vs. no)1.27 (1.00-1.61)0.048Bone metastases (yes vs. no)1.18 (0.94–1.49)0.150aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, PFS Progression free survival Table 3Multivariable Cox regression analysis for PFSCovariatesCox regressionaHR (95% CI)p-valueECOG-PS (2 vs. 0–1)1.51 (1.12–2.03)0.007Age (≥ 70 vs. <70 years)0.93 (0.75–1.16)0.533Sex (female vs. male)1.20 (0.93–1.53)0.158Histology (mixed vs. pure UC)1.61 (1.24–2.09)< 0.001Liver metastases (yes vs. no)1.27 (1.00-1.61)0.048Bone metastases (yes vs. no)1.18 (0.94–1.49)0.150aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, PFS Progression free survival Multivariable Cox regression analysis for PFS aHR Adjusted hazard ratio, CI Confidence interval, ECOG-PS Eastern Cooperative Oncology Group Performance Status, PFS Progression free survival These adjusted analyses support an independent association between ECOG-PS 2 and worse outcomes, although residual confounding related to disease burden and prior treatment trajectory cannot be excluded. OS according to metastatic sites Overall, shorter OS in ECOG-PS 2 was observed in those with liver, bone, lymph node, and lung metastases, whereas no statistically significant differences were found in patients with brain or soft tissue metastases (Fig. 3). Detail subgroup-specific median OS estimates, hazard ratios, p-value, and 12-months OS rates are reported in Supplementary Table S4. Fig. 3Overall survival according to metastatic sites (A, liver; B, bone; C, lung; D: lymph nodes; E: brain; F: soft tissue) Overall survival according to metastatic sites (A, liver; B, bone; C, lung; D: lymph nodes; E: brain; F: soft tissue) PFS according to metastatic sites By metastatic site, ECOG-PS 2 was associated with shorter PFS in patients with lymph nodes and bone metastases, while no statistically significant differences were detected in patients with liver, lung, brain or soft tissue metastases (Fig. 4). Subgroup-specific median PFS estimates, hazard ratios, p-values, and 12-month PFS rates are summarized in Supplementary Table S5. Fig. 4Progression-free survival according to metastatic sites (A, liver; B, bone; C, lung; D: lymph nodes; E: brain; F: soft tissue) Progression-free survival according to metastatic sites (A, liver; B, bone; C, lung; D: lymph nodes; E: brain; F: soft tissue) Univariate and multivariate survival analysis in patients with ECOG-PS 2 In the complete-case subgroup of patients with ECOG-PS 2, comprising 82 patients and 47 OS events, none of the prespecified variables was significantly associated with OS in univariable analyses, and no independent prognostic association was identified in the multivariable model. (Table 4). A broadly similar pattern was observed for PFS. In the ECOG-PS 2 complete-case subgroup, including 80 patients and 56 PFS events, no prespecified variable was significantly associated with PFS in either univariable or multivariable analyses, (Table 5). Table 4Univariate and multivariate for overall survival among patients with ECOG-PS 2Overall SurvivalUnivariate Cox regressionMultivariate Cox regressionHR (95% CI)p-valueHR (95% CI)p-valueAge ≥ 70 years (yes versus no)0.87 (0.49–1.54)0.6311.02 (0.54–1.92)0.949Histology (mixed versus pure UC)1.11 (0.56–2.18)0.7651.23 (0.61–2.45)0.566Upper versus lower urinary tract1.15 (0.60–2.19)0.6811.11 (0.56–2.18)0.770Liver metastases (yes versus no)1.47 (0.82–2.63)0.1941.50 (0.78–2.88)0.223Bone metastases (yes versus no)1.22 (0.68–2.19)0.4991.10 (0.58–2.07)0.779 Table 4Univariate and multivariate for overall survival among patients with ECOG-PS 2Overall SurvivalUnivariate Cox regressionMultivariate Cox regressionHR (95% CI)p-valueHR (95% CI)p-valueAge ≥ 70 years (yes versus no)0.87 (0.49–1.54)0.6311.02 (0.54–1.92)0.949Histology (mixed versus pure UC)1.11 (0.56–2.18)0.7651.23 (0.61–2.45)0.566Upper versus lower urinary tract1.15 (0.60–2.19)0.6811.11 (0.56–2.18)0.770Liver metastases (yes versus no)1.47 (0.82–2.63)0.1941.50 (0.78–2.88)0.223Bone metastases (yes versus no)1.22 (0.68–2.19)0.4991.10 (0.58–2.07)0.779 Univariate and multivariate for overall survival among patients with ECOG-PS 2 Table 5Univariate and multivariate survival analysis for progression-free survival among patients with ECOG-PS 2Progression Free SurvivalUnivariate Cox regressionMultivariate Cox regressionHR (95% CI)p-valueHR (95% CI)p-valueAge ≥ 70 years (yes versus no)0.86 (0.51–1.47)0.5870.89 (0.50–1.61)0.705Histology (mixed versus pure UC)1.68 (0.93–3.02)0.0831.73 (0.95–3.15)0.073Upper versus lower urinary tract1.23 (0.67–2.23)0.5041.24 (0.66–2.31)0.517Liver metastases (yes versus no)1.08 (0.64–1.84)0.7691.08 (0.60–1.96)0.799Bone metastases (yes versus no)1.22 (0.72–2.07)0.36801.10 (0.63–1.95)0.730 Table 5Univariate and multivariate survival analysis for progression-free survival among patients with ECOG-PS 2Progression Free SurvivalUnivariate Cox regressionMultivariate Cox regressionHR (95% CI)p-valueHR (95% CI)p-valueAge ≥ 70 years (yes versus no)0.86 (0.51–1.47)0.5870.89 (0.50–1.61)0.705Histology (mixed versus pure UC)1.68 (0.93–3.02)0.0831.73 (0.95–3.15)0.073Upper versus lower urinary tract1.23 (0.67–2.23)0.5041.24 (0.66–2.31)0.517Liver metastases (yes versus no)1.08 (0.64–1.84)0.7691.08 (0.60–1.96)0.799Bone metastases (yes versus no)1.22 (0.72–2.07)0.36801.10 (0.63–1.95)0.730 Univariate and multivariate survival analysis for progression-free survival among patients with ECOG-PS 2 Safety data No statistically significant differences were observed between the ECOG-PS 0–1 and ECOG-PS 2 groups in the proportion of patients experiencing ≥ 1 grade3-4 prespecified toxicity (19.5% vs. 22.4%, p = 0.544), any subsequent dose reduction (38.3% vs. 32.9%, p = 0.351), or skipping ≥ 1 EV administration due to toxicity (25.7% vs. 27.4%, p = 0.751). Individual grade 3–4 toxicities were compared descriptively and showed numerical differences between groups, with cutaneous toxicity reported in 5.8% versus 3.5%, neuropathy in 6.0% versus 9.4%, diarrhea in 15.2% versus 7.1% and diabetes in 1.2% versus 3.5% of patients in the ECOG-PS 0–1 and ECOG-PS 2 groups, respectively. Most patients received a standard EV starting dose in both groups, although the use of a reduced starting dose appeared more frequent among ECOG-PS 2 (17.6% vs. 7.5%). (Table 6). Data on permanent discontinuation of EV due to toxicity were not systematically available across centers. Table 6Grade 3–4 AEs and dose management among ECOG-PS patientsOncology CenterNumber of patientsAMO (Assistência Multidisciplinar em Oncologia) - DASA, Brazil1AORN Antonio Cardarelli, Napoli1ARNAS Civico Di Cristina Benfratelli, Palermo12ASL Latina, Ospedale di Aprilia2Ankara University School of Medicine3Attikon University Hospital, Athens10Azienda Ospedaliera San Camillo-Forlanini, Roma14Azienda Ospedaliera Universitaria Federico II, Napoli12Azienda Ospedaliera Universitaria Integrata di Verona6Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro20Azienda Ospedaliero-Universitaria Careggi, Firenze8Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari15Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara5Azienda Ospedaliero-Universitaria Pisana12Azienda Ospedaliero-Universitaria di Parma13Azienda Sanitaria Territoriale Pesaro Urbino, San Salvatore1Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul9Centre Hospitalier de Jolimont7Centro Paulista de Oncologia, Sao Paulo3Cliniques Universitaires Saint-Luc, Brussels8Fondazione IRCCS Istituto Nazionale dei Tumori, Milano21Hospital Universitario Insular de Gran Canaria8Hospital Universitario La Paz, Madrid6Hospital Universitario Ramón y Cajal, Madrid26Hospital de la Santa Creu i Sant Pau, Barcelona2Hospital Ángeles del Pedregal, Mexico City1IRCCS Azienda Ospedaliero-Universitaria di Bologna - Sant’Orsola12IRCCS Istituti Fisioterapici Ospitalieri - Regina Elena, Roma5IRCCS Istituto Oncologico Veneto (IOV), Padova33IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola - Cesena - Forli20IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo6IRCCS Ospedale Policlinico San Martino, Genova5Instituto Alexander Fleming, Buenos Aires5Istituto Europeo di Oncologia (IEO), Milano8Korea University Anam Hospital20MD Anderson Cancer Center Madrid12Maria Sklodowska-Curie National Research Institute, Warsaw15Markey Cancer Center, University of Kentucky21Masaryk Memorial Cancer Institute (MOU), Brno2Medical University of Innsbruck16National Cancer Centre Singapore4Ospedale Santa Corona, Pietra Ligure7Ospedale Santa Maria delle Croci, Ravenna4Ospedale Santa Maria delle Grazie, Pozzuoli8Ospedale di Civitanova Marche (AST Macerata)2Policlinico Umberto I, Sapienza University of Rome6Saitama Medical Center, Jichi Medical University, Japan26The Jikei University Hospital, Tokyo9Thomayer University Hospital, Prague1University Hospital Bonn24University Hospital Motol, Prague2University Hospital Olomouc (FNOL)6University Hospital Pilsen13University Medical Center Schleswig-Holstein, Campus Lübeck1University of Kansas Cancer Center48Winship Cancer Institute of Emory University8 Table 6Grade 3–4 AEs and dose management among ECOG-PS patientsOncology CenterNumber of patientsAMO (Assistência Multidisciplinar em Oncologia) - DASA, Brazil1AORN Antonio Cardarelli, Napoli1ARNAS Civico Di Cristina Benfratelli, Palermo12ASL Latina, Ospedale di Aprilia2Ankara University School of Medicine3Attikon University Hospital, Athens10Azienda Ospedaliera San Camillo-Forlanini, Roma14Azienda Ospedaliera Universitaria Federico II, Napoli12Azienda Ospedaliera Universitaria Integrata di Verona6Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro20Azienda Ospedaliero-Universitaria Careggi, Firenze8Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari15Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara5Azienda Ospedaliero-Universitaria Pisana12Azienda Ospedaliero-Universitaria di Parma13Azienda Sanitaria Territoriale Pesaro Urbino, San Salvatore1Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul9Centre Hospitalier de Jolimont7Centro Paulista de Oncologia, Sao Paulo3Cliniques Universitaires Saint-Luc, Brussels8Fondazione IRCCS Istituto Nazionale dei Tumori, Milano21Hospital Universitario Insular de Gran Canaria8Hospital Universitario La Paz, Madrid6Hospital Universitario Ramón y Cajal, Madrid26Hospital de la Santa Creu i Sant Pau, Barcelona2Hospital Ángeles del Pedregal, Mexico City1IRCCS Azienda Ospedaliero-Universitaria di Bologna - Sant’Orsola12IRCCS Istituti Fisioterapici Ospitalieri - Regina Elena, Roma5IRCCS Istituto Oncologico Veneto (IOV), Padova33IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola - Cesena - Forli20IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo6IRCCS Ospedale Policlinico San Martino, Genova5Instituto Alexander Fleming, Buenos Aires5Istituto Europeo di Oncologia (IEO), Milano8Korea University Anam Hospital20MD Anderson Cancer Center Madrid12Maria Sklodowska-Curie National Research Institute, Warsaw15Markey Cancer Center, University of Kentucky21Masaryk Memorial Cancer Institute (MOU), Brno2Medical University of Innsbruck16National Cancer Centre Singapore4Ospedale Santa Corona, Pietra Ligure7Ospedale Santa Maria delle Croci, Ravenna4Ospedale Santa Maria delle Grazie, Pozzuoli8Ospedale di Civitanova Marche (AST Macerata)2Policlinico Umberto I, Sapienza University of Rome6Saitama Medical Center, Jichi Medical University, Japan26The Jikei University Hospital, Tokyo9Thomayer University Hospital, Prague1University Hospital Bonn24University Hospital Motol, Prague2University Hospital Olomouc (FNOL)6University Hospital Pilsen13University Medical Center Schleswig-Holstein, Campus Lübeck1University of Kansas Cancer Center48Winship Cancer Institute of Emory University8 Grade 3–4 AEs and dose management among ECOG-PS patients Discussion EV, an ADC targeting Nectin-4, showed considerable clinical benefit compared to systemic chemotherapy in the randomized phase III EV-301 study [9]. In this trial including 608 patients with locally advanced unresectable or metastatic UC who had prior treatments with platinum-based chemotherapy and PD-1/PD-L1 inhibitors, EV showed increased OS and PFS when compared to chemotherapy. Moreover, response rates were greater with enfortumab vedotin compared to chemotherapy (41% versus 19%). However, EV-301 clinical trial included only patients with ECOG-PS 0 or 1, while ECOG-PS 2 mUC patients were excluded [10]. Therefore, in this patient subgroup, the effectiveness of EV monotherapy remains uncertain and can only be inferred from non-randomized prospective trials and studies based on “real world evidence.” In clinical settings, the actual benefit of EV for this group of vulnerable patients remains a significant and yet unresolved clinical question [11]. ECOG-PS assesses a patient’s capacity for self-care, daily activities, and physical functioning regarding walking and working, or the proportion of waking hours spent restricted to bed or a chair [12, 13]. As a result, this assessment is quite heterogeneous and relies on the personal classification of each individual physician, meaning that various doctors may assess a single patient in different ways, leading to a varied group of patients within the same ECOG-PS level. Notwithstanding this, ECOG-PS continues to be an important and reliable variable, ranking among the most significant independent prognostic indicators in various tumors, including mUC [14, 15]. Based on these premises, our multicenter, real-world analysis provides evidence on the outcomes of EV monotherapy in pretreated mUC patients with ECOG-PS 2, a population that remains underrepresented in prospective trials. First, our study suggests that, as previously suggested for chemotherapy, immunotherapy and targeted agents in this setting – including our previous experience exploring pembrolizumab in ECOG-PS 2 mUC [16, 17], PS at the beginning of the treatment retains prognostic significance in patients treated with EV. Importantly, these findings should not be interpreted as evidence that EV is intrinsically less effective in ECOG-PS 2 patients. Rather, ECOG-PS 2 likely identifies a subgroup with poorer baseline prognosis, greater disease burden, and clinical frailty, all of which may contribute to shorter OS and PFS. In our analysis, we confirmed that ECOG-PS is associated with shorter OS and PFS, in the overall population as well as according to several metastatic sites, such as liver, lung, bone, and lymph nodes metastases. In our cohort, patients with ECOG-PS 2 more frequently had liver and bone metastases, and also showed a higher prevalence of brain metastases, supporting the possibility that worse outcomes partly reflect more aggressive or more clinically advanced disease at EV initiation. At the same time, no prognostic factors were identified considering both univariate and multivariate analysis in ECOG-PS 2 patients. Our study specifically addresses EV monotherapy in a pretreated population and does not inform whether earlier use of EV-based combinations, such as EV plus pembrolizumab, might mitigate the poor outcomes observed in patients who eventually receive EV with ECOG-PS 2. The major limitations of our study are its retrospective design, which may have influenced our findings. In fact, the retrospective design and lack of data on comorbidities and concomitant medication usage in the study population pose a problem due to potential confounding errors and biases. The lack of an independent radiological central review may also increase the likelihood of incorrectly interpreting treatment response evaluations. Accordingly, PFS was treated as a descriptive time-to-event outcome derived from local clinical practice, and not as a centrally adjudicated efficacy endpoint. Furthermore, we were unable to account for nutritional status beyond baseline BMI. More informative markers such as recent weight loss, albumin, sarcopenia, or inflammation-based nutritional scores were not available, and residual confounding related to cancer-associated malnutrition may have affected outcomes, particularly among ECOG-PS 2 patients. In addition, the lack of genomic evaluation of tumor tissue to detect molecular alterations such as FGFR mutation / fusion, HER2 amplification and/or overexpression, and limited information on patient and treatment characteristics are issues to be considered. In the end, residual confounding remains a major limitation of this analysis, as ECOG-PS 2 may partly reflect cancer-related clinical decline and poorer baseline prognosis rather than performance status alone, while the lack of granular data on prior platinum/ICI benefit and exact EV treatment line may also have contributed to the worse outcomes observed in this group. Although the difference between the full cohort and the complete-case population was relatively small, some degree of bias cannot be excluded if missingness was not random. At the same time, given the overall large sample size and the high number of centers and countries included in the study, our results may represent a topic of reflection for healthcare professionals, especially in countries and geographic areas where novel combinations (such as first-line EV plus pembrolizumab according to EV-302) are not available yet [18, 19]. Moreover, it appears important to validate alternative measurement instruments for functional performance that may be less subjective and better suited to tackle the diversity of domains influencing PS. Currently, the issue regarding the predictive value of response to EV for ECOG-PS 2 remains unresolved. Conclusions Our analysis showed shorter OS and PFS in pretreated mUC patients with ECOG-PS 2 receiving EV monotherapy. The outcomes of EV monotherapy in ECOG-PS 2 patients remains uncertain and can only be inferred from non-randomized prospective studies and real world evidence. Further studies and multicentric translational collaborations are needed to validate these findings. Supplementary Information Supplementary Material 1: Table S1. List of participating centers and number of patients registred in ARON-2EV. Table S2. Sensitivity analysis: multivariable Cox regression analysis for OS. Table S3. Sensitivity analysis: multivariable Cox regression analysis for PFS. Table S4. Subgroup analyses for OS by metastatic sites. Table S5. Subgroup analyses for PFS by metastatic sites. Supplementary Material 1: Table S1. List of participating centers and number of patients registred in ARON-2EV. Table S2. Sensitivity analysis: multivariable Cox regression analysis for OS. Table S3. Sensitivity analysis: multivariable Cox regression analysis for PFS. Table S4. Subgroup analyses for OS by metastatic sites. Table S5. Subgroup analyses for PFS by metastatic sites.